Gives criteria for evaluating and diagnosing bleeding disorders in newborns and tells how to differentiate such disorders in newborns, children, and adults.
Tebipenem HBr cUTI trial ends early after meeting efficacy goals
May 28th 2025GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.
Read More